MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.
Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, we describe the use of the restricted mean survival time as a possible alternative tool in the design and analysis of these trials.
The restricted mean is a measure of average survival from time 0 to a specified time point, and may be estimated as the area under the survival curve up to that point. We consider the design of such trials according to a wide range of possible survival distributions in the control and research arm(s). The distributions are conveniently defined as piecewise exponential distributions and can be specified through piecewise constant hazards and time-fixed or time-dependent hazard ratios. Such designs can embody proportional or non-proportional hazards of the treatment effect.
We demonstrate the use of restricted mean survival time and a test of the difference in restricted means as an alternative measure of treatment effect. We support the approach through the results of simulation studies and in real examples from several cancer trials. We illustrate the required sample size under proportional and non-proportional hazards, also the significance level and power of the proposed test. Values are compared with those from the standard approach which utilizes the logrank test.
We conclude that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial. Restricted mean survival time may provide a practical way forward and deserves greater attention.
具有时间事件结局的临床试验的设计和分析几乎总是依赖于风险比来估计治疗效果,因此隐含地依赖于比例风险假设。然而,最近一些试验的结果表明,不能保证该假设成立。在这里,我们描述了使用受限平均生存时间作为这些试验的设计和分析的一种可能的替代工具。
受限平均是从时间 0 到指定时间点的平均生存时间的度量,可以估计为该点之前生存曲线下的面积。我们根据对照和研究臂中广泛的可能生存分布来考虑这种试验的设计。这些分布方便地定义为分段指数分布,可以通过分段常数风险和时间固定或时间依赖的风险比来指定。这种设计可以体现治疗效果的比例或非比例风险。
我们展示了受限平均生存时间和受限平均差异检验的使用,作为治疗效果的替代衡量指标。我们通过模拟研究和来自几个癌症试验的实际例子的结果支持了这种方法。我们说明了在比例和非比例风险下的所需样本量,以及所提出检验的显著性水平和功效。与利用对数秩检验的标准方法相比,给出了这些值。
我们得出结论,风险比不能作为随机对照试验中治疗效果的一般衡量标准,在设计试验时也不总是合适的。受限平均生存时间可能提供了一种实用的方法,值得更多关注。